ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Furthermore, imatinib inhibits the expression of the glucose transporter Glut1 in BCR-ABL-positive, but not in BCR-ABL-negative, chronic myeloid leukemia cells [40].